Short Communication: Evaluating the Level of Expressed HIV Type 1 gp120 and gag Proteins in the vCP1521 Vector by Two Immunoplaque Methods

Abstract

Over the past few years, several recombinant ALVAC constructs have been used as delivery systems in various vaccine research studies and trials. The ALVAC-HIV vCP1521 vector has been used as a vaccine delivery system in the RV144 study, a phase III HIV study that displayed over 31% protective efficacy. One of the important parameters for evaluating the potency of an ALVAC construct is the stable expression of proteins encoded by the inserted genes. Herein, the expression of inserted gp120 and gag genes in two manufactured ALVAC-HIV vCP1521 lots have been determined by two immunoplaque methods (dish and plaque lift). Both methods were specific and robust and demonstrated that the ALVAC-HIV vCP1521 lots were able to express gp120 and gag proteins in over 99% of the infectious plaques.

Get full access to this article

View all access options for this article.

References

Minke

, Fischer

, Baudu

et al. Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination. Vet Immunol Immunopathol, 2006; 111,1–2:47–57.

van Baren

, Bonnet

, Dreno

et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol, 2005; 23,35:9008–9021.

Johnson

, McFarland

, Muresan

et al. Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women. J Infect Dis, 2005; 192,12:2129–2133.

, Minke

, Rehder

et al. A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse. Vet Immunol Immunopathol, 2008; 123,3–4:230–239.

Kyriakis

, De Vleeschauwer

, Barbe

, Bublot

, Van

. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs. Vaccine, 2009; 27,16:2258–2264.

Rerks-Ngarm

, Pitisuttithum

, Nitayaphan

et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med, 2009; 361,23:2209–2220.

Welter

, Taylor

, Tartaglia

, Paoletti

, Stephensen

. Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection, using recombinant attenuated poxvirus vaccines. J Virol, 2000; 74,14:6358–6367.

Rosenwirth

, Kuhn

, Heeney

et al. Safety and immunogenicity of ALVAC wild-type human p53 (vCP207) by the intravenous route in rhesus macaques. Vaccine, 2001; 19,13–14:1661–1670.

Siemens

, Crist

, Austin

, Tartaglia

, Ratliff

. Comparison of viral vectors: Gene transfer efficiency and tissue specificity in a bladder cancer model. J Urol, 2003; 170,3:979–984.

10.

Gene Transfer Medicinal Products For Human UseSection 5.14, European Pharmacopoeia 7.0.

11.

WHO informal consultation on characterization and quality aspects of vaccines based on live viral vectors. WHO: Geneva HQ, December 4–5, 2003.

12.

Pitisuttithum

, Rerks-Ngarm

, Bussaratid

et al. Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand. PLoS One, 2011; 6,12:e27837.

13.

Rerks-Ngarm

, Pitisuttithum

, Nitayaphan

et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med, 2009; 361,23:2209–2220.

14.

Paris

, Bejrachandra

, Thongcharoen

et al. HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX((R)) B/E. Vaccine, 2012; 30,5:832–836.

15.

Vaccari

, Poonam

, Franchini

. Phase III HIV vaccine trial in Thailand: A step toward a protective vaccine for HIV. Expert Rev Vaccines, 2010; 9,9:997–1005.